当前位置：药药网 / 医药文献 /临床试验研究设计终点和生物标志物药物安全性(本栏目收费,不能显示细节,电话13136136841)
关键字：
类型：
下载页码(大于等于0,小于611)：
临床试验研究设计终点和生物标志物药物安全性 890条(本栏目收费,不能显示细节,电话13136136841)
prognostic biomarker validation,259–261
259 261
study design inclusion,330
330
surrogate marker criteria,331
331
thymidine phosphorylase as survival biomarker,248–249
248 249
Biostatistics comparison analysis,175–176
175 176
hazard ratio calculation,171–172
171 172
Kaplan-Meier plot censoring data,168–169,172
168 169 172
time of enrollment and data,172–174
172 174
one-tailed test,176–177
176 177
hypothesis testing,177–180
177 180
superiority analysis versus non-inferiority analysis,187–190
187 190
two-tailed test,176–177
176 177
Black box warning,565–567
565 567
Decision aid informed consent,556–558
556 558
Decision tree Baselga schema,31
31
run-in period,59–60
59 60
Dendritic cell (DC)classification,487–488
487 488
ABC transporters,76–78
76 78
AC see Active control Active control (AC),24,27,44–46
24 27 44 46
Active placebo,133–134
133 134
Acute lymphocytic leukemia (ALL)clinical features,284–287
284 287
cytogenetics for diagnosis and prediction,300–304,323
300 304 323